# Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

> **NCT01126099** · NA · COMPLETED · sponsor: **Seattle Institute for Biomedical and Clinical Research** · enrollment: 20 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Prazosin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01126099
- **Lead sponsor:** Seattle Institute for Biomedical and Clinical Research
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-05-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01126099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01126099, "Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01126099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*